Initiate patients on the Dexcom G7 15 Day and Dexcom G7 Continuous Glucose Monitoring (CGM) Systems for better assessment of glycemic control after discharge1 — at no cost to your hospital.
Company Background
Dexcom, Inc. empowers people to take control of their health through innovative biosensing technology. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. For more than 25 years, Dexcom’s technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.
Product Overview
Dexcom offers CGM solutions for all patients with diabetes. Dexcom CGM systems are the most accurate CGM systems2 with intuitive, easy-to-use designs for a user-friendly experience. Dexcom CGM sends real-time glucose readings to a smart device or handheld receiver via a small sensor worn on the body. This allows patients to see where their glucose levels are and how fast they are rising or falling. It also sends alerts to help them take action to avoid dangerously high or low glucose levels.
Dexcom CGM may help patients manage their diabetes following hospital discharge. The Dexcom hospital discharge program provides a trial of Dexcom G7 15 Day for adult patients or Dexcom G7 for pediatric patients discharged from the hospital who have been identified as appropriate candidates.
Dexcom’s hospital discharge program is designed to decrease readmissions. A prospective, nonrandomized study showed that initiating Dexcom CGM* at hospital discharge is associated with significant glycemic improvements in patients with type 2 diabetes on basal insulin. A1C decreased from 11.7% to 8.2% (P <0.0001). Time below 70 mg/dL was <1% at all times.3 Real-world evidence also demonstrates glycemic and emotional benefits of Dexcom CGM initiation at discharge. A1C decreased 3.2% after 12 weeks of Dexcom CGM use. Change in median Diabetes Distress Scale score improved significantly from 2.65 to 1.76 (P <0.001) after 12 weeks of Dexcom CGM use.4 With Dexcom CGM use, patients reduced their diabetes-related inpatient admission costs by 35%†,5 and reduced their diabetes-related inpatient visits by 50%.‡,6
Dexcom Clarity helps care teams stay connected with patients following hospital discharge and can keep providers updated between visits. Following hospital discharge, patients can share their glucose readings with their care team through their Dexcom app. Healthcare providers can evaluate relevant retrospective patterns and trends in Clarity to help with diabetes management. Initiate patients on Dexcom CGM for better assessment of glycemic control after discharge.1
Testimonials
- Dexcom is the most affordable CGM brand at pharmacy§,2
- Dexcom CGM is clinically proven to lower A1C7-11
- Most covered patients pay $20 or less per month for Dexcom CGM§,2
- Dexcom ranks #1 in patient satisfaction, ‖ adherence,¶ and retention12,13
Ordering Information
To learn more about the Dexcom hospital discharge program, visit provider.dexcom.com/discharge.
*Study participants used Dexcom G6. † Retrospective analysis of Optum Research Database administrative claims data for patients with T2D (N = 571) after initiation of Dexcom CGM. ‡ Retrospective analysis of US healthcare claims data using Optum’s Clinformatics® database in patients with T2D on intensive insulin therapy who initiated Dexcom CGM. Diabetes-related events were assessed 12 months pre- and post-index. § Individual pricing may vary depending on insurance coverage. IQVIA FIA retail data, paid sensor claims. ‖ Based on a 2025 comparison in net promoter scores across major CGM brands. ¶ Self-reported daily use.
1 Galindo RJ, et al. Diabetes. 2021;70(Suppl 1):613-P. 2 Dexcom, data on file, 2025. 3 Wallace C, et al. J Endocr Soc. 2025;10(1):bvaf169. 4 Folk S, et al. Diabetes. 2025;74(Suppl 1):2033-LB. 5 Norman GJ, et al. Diabetes Technol Ther. 2022;24(7):520-524. 6 Hannah KL, et al. Adv Ther. 2024;41(6):2299-2306. 7 Beck RW, et al. JAMA. 2017;317(4):371-378. 8 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374. 9 Martens T, et al. JAMA. 2021;325(22):2262-2272. 10 Garg SK, et al. Diabetes Technol Ther. 2025;27(6):413-502. 11 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-147. 12 Dexcom, data on file, 2024. 13 Seagrove Patient Perspectives 2025.
